Abstract
Despite obvious successes in controlling most serious childhood infections, there is a need to develop cheaper and more effective programs in infant vaccination. However, with the knowledge that adults are susceptible to diseases once believed to be only relevant to children, these criteria are equally applicable to adult vaccination programs. Furthermore, with the emphasis on safety, the vaccine industry is slowly replacing existing vaccines with recombinant alternatives that are safer and less reactogenic than their nonrecombinant counterparts, yet also less immunogenic. Thus, any improvements to vaccines in the foreseeable future are likely to arise through the introduction of better adjuvants and delivery systems. For example, a single injection comprising primary and booster doses of vaccine would improve compliance in a cost-effective manner by reducing the number of visits to clinics or medical centers. Equally, administering existing vaccines orally would remove the trauma of injection and the reliance on medical staff to perform the injections. Many vaccines are dependent on a cold chain; improving the stability of vaccines would thus help to reduce the cost of vaccination. To tackle such issues, researchers have borrowed ideas from other areas of the pharmaceutical industry in an attempt to improve the performance of vaccines and reduce the cost of these important health-care interventions.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Beck, L. E., Pope, V. Z., Flowers, C. E., Cowsar, D. R., Tice, T. R., Lewis, D. H., et al. (1983) Poly(DL-lactide-co-glycolide)/norethisterone microparticles: an injectable biodegradable contraceptive. Biol. Reprod. 28, 186–195.
Verrijk, R., Smolders, I. J. H., Bosnie, N., and Begg, A. C. (1992) Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide. Cancer Res. 52, 6653–6656.
Kohn, J., Niemi, S. M., Albert, E. C., Murphy, J. C., Langer, R., and Fox, J. (1986) Single-step immunization using controlled release biodegradable polymer with sustained adjuvant activity. J. Immunol. Methods 95, 31–38.
Morris, W., Steinhoff, M. C., and Russell, P. K. (1994) Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12, 5–11.
Walker, R. I. (1994) New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12, 387–400.
Reul, G. J. (1977) Use of vicryl (polyglactin 910) sutures in general surgery and cardiothoracic procedures. Am. J. Surg. 134, 297–299.
Vert, M., Christel, P., Chabot, F., and Leray, L.F. (1984) Bioresorbable plastic materials for bone surgery, in Macromolecular Biomaterials (Hastings, H. W. and Ducheyne, P., eds.), CRC Press, Boca Raton, FL, pp. 119–142.
Visscher, G. E., Robinson, R. L., Maulding, H. V., Fong, J. W., Pearson, J. E., and Argentieri, G. J. (1985) Biodegradation and tissue reaction to 50∶50 poly(D,L-lactide-co-glycolide) microparticles. J. Biomed. Mater. Res. 19, 349–365.
Wise, D. L., Fellman, T. D., Sanderson, J. E., and Wentworth, R. L. (1979) Lactic/glycolic acid polymers, in Drug Carriers in Biology and Medicine (Gregoriadis, G., ed.), Academic Press, London, pp. 237–270.
Vert, M., Li, S., and Garreau, H. (1991) More about the degradation of LA/GA-derived matrices in aqueous media. J. Control. Rel. 16, 15–26.
Cohen, S., Yoshioka, T., Lucarelli, M., Hwang, L. H., and Langer, R. (1991) Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8, 713–720.
Aguado, M. T. and Lambert, P.-H. (1992) Controlled release vaccines—biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology 184, 113–125.
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., McGhee, J. R., Tice, T. R., and Gilley, R.M. (1991) Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28, 287–294.
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., and Gilley, R.M. (1991) Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59, 2978–2986.
Eldridge, J. H., Hammond, C. J., Meulbroek, J. A., Staas, J. K., Gilley, R. M., and Tice, T. M. (1990) Controlled vaccine release in the gut-associated lymphoid tissues. 1. Orally administered biodegradable microspheres target the Peyer’s patches. J. Control. Rel. 11, 205–214.
Mestecky, J., Moldoveanu, Z., Novak, M., Huang, W-Q., Gilley, R. M., Staas, J. K., et al. (1994) Biodegradable microspheres for the delivery of oral vaccines. J. Control. Rel. 28, 131–141.
Bockman, D. E. and Cooper, M. D. (1973) Pinocytosis by epithelium associated with lymphoid follicles in the bursa of Fabricius, appendix and Peyer’s patches. An electron microscope study. Am. J. Anat. 136, 455–477.
O’Hagan, D. T. (1990) Intestinal translocation of particulates—implications for drug and antigen delivery. Adv. Drug Delivery Rev. 5, 265–285.
Challacombe, S. J., Rahman, D., Jeffery, H., Davis, S. S., and O’Hagan, D. T. (1992) Enhanced secretory IgA and systemic IgG antibody responses after oral immunisation with biodegradable microparticles containing antigen. Immunology 76, 164–168.
Maloy, K. J., Donachie, A. M., O’Hagan, D. T., and Mowat, A. McI. (1994) Induction of mucosal and systemic immune responses by immunisation with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81, 661–667.
Corthesy, B. and Spertini, F. (1999) Secretory immunoglobulin A: from mucosal protection to vaccine development. Biol. Chem. 380, 1251–1262.
Chen, H. (2000) Recent advances in mucosal vaccine development. J. Control. Release 67, 117–128.
van Ginkel, F. W., Nguyen, H. H., and McGhee, J. R. (2000) Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg. Infect. Dis. 6, 123–132.
Gupta, R. K., Singh, M., and O’Hagan, D. T. (1998) Poly(lactide-co-glycolide) micro-particles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev. 6, 225–246.
Jones, D. H., McBride, B. W., Jeffery, H., O’Hagan, D. T., Robinson, A., and Farrar, G. H. (1995) Protection of mice from Bordetella pertussis respiratory infection using microen-capsulated pertussis fimbriae. Vaccine 13, 675–681.
Jones, D. H., Partidos, C. D., Steward, M. W., and Farrar, G. H. (1997) Oral administration of poly(lactide-co-glycolide) encapsulated vaccines. Behring Inst. Mitt. 98, 220–228.
Raghuvanshi, R. S., Goyal, S., Singh, O., and Panda, A. K. (1998) Stabilization of dichloromethane-induced protein denaturation during microencapsulation. Pharm. Dev. Tech. 3, 269–276.
Xing, D. K.-L., Crane, D. T., Bolgiano, B., Corbel, M. J., Jones, C., and Sesardic, D. (1996) Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. Vaccine 14, 1205–1213.
Takahata, H., Lavelle, E. C., Coombes, A. G. A., and Davis, S. S. (1998) The distribution of protein associated with poly(DL-lactide-co-glycolide) microparticles and its degradation in simulated body fluids. J. Control. Rel. 50, 237–248.
Chang, A. C. and Gupta, R. K. (1996) Stabilization of tetanus toxoid in poly(DL-lactide-co-glycolide) microspheres for the controlled release of antigen. J. Pharm. Sci. 85, 129–132.
Johansen, P., Men, Y., Audran, R., Corradin, G., Merkle, H. P., and Gander, B. (1998) Improved stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res. 15, 1103–1110.
Audran, R., Men, Y., Johansen, P., Gander, B., and Corradin, G. (1998) Enhanced immuogenicity of microencapsulated tetanus toxoid with stabilizing agents. Pharm. Res. 15, 1111–1116.
Schwendeman, S. P., Tobio, M., Joworowicz, M., Alonso, M. J., and Langer, R. (1998) New strategies for the microencapsulation of tetanus vaccine. J. Microencapsul. 15, 299–318.
Schwendeman, S. P., Constantino, H. R., Gupta, R. K., Siber, G. R., Klibanov, A. M., and Langer, R. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc. Natl. Acad. Sci. USA 92, 11,234–11,238.
Lavelle, E. C., Yeh, M.-K., Coombes, A. G. A., and Davis, S. S. (1999) The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine 17, 512–529.
Jabbal-Gill, I., Lin, W., Jenkins, P., Watts, P., Jimenez, M., Illum, L., et al. (2000) Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18, 238–250.
Singh, M., Briones, M., Ott, G., and O’Hagan, D. (2000) Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA 97, 811–816.
Jeffery, H., Davis, S. S., and O’Hagan, D. T. (1993) The preparation and characterisation of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm. Res. 10, 362–368.
Eldridge, J. H., Staas, J. K., Meulbroek, J. A., Tice, T. R., and Gilley, R. M. (1991) Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59, 2978–2986.
Alonso, M. J., Gupta, R. K., Min, C., Siber, G. R., and Langer, R. (1994) Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 12, 299–306.
Cleland, J. L., Powell, M. F., Lim, A., Barron, L., Berman, P. W., Eastman, D. J., et al. (1994) Development of a single-shot subunit vaccine for HIV-1. AIDS Res. Hum. Retrovir. 10, S21–S26.
Jones, D. H., Corris, S., McDonald, S., Clegg, J. C. S., and Farrar, G. H. (1997) Poly(DL-lactide-co-glycolide) encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 15, 814–817.
Jones, D. H., Clegg, J. C. S., and Farrar, G. H. (1998) Oral delivery of microencapsulated DNA vaccines. Dev. Biol. Stand. 92,149–155.
Chen, S. C., Jones, D. H., Fynan, E. F., Clegg, J. C. S., Farrar, G. H., Greenberg, H. B., et al. (1998) Mucosal immunity induced by oral immunization with a rotavirus VP6 DNA vaccine encapsulated in microparticles. J. Virol. 72, 5757–5761.
Jones, T. (1998) Mucosal Immunity elicited by DNA Vaccines. IDrugs 1, 103–108.
Herrmann, J. E., Chen, S. C., Jones, D. H., Tinsley-Bown, A., Fynan, E. F., Greenberg, H. B., et al. (1999) Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA Vaccines encapsulated in microparticles. Virology 259, 148–153.
Coombes, A. G. A., Lavelle, E. C., and Davis, S. S. (1999) Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein. Vaccine 17, 2410–2422.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Jones, D.H. (2003). Microencapsulation of Vaccine Antigens. In: Robinson, A., Hudson, M.J., Cranage, M.P. (eds) Vaccine Protocols. Methods in Molecular Medicine™, vol 87. Humana Press. https://doi.org/10.1385/1-59259-399-2:211
Download citation
DOI: https://doi.org/10.1385/1-59259-399-2:211
Publisher Name: Humana Press
Print ISBN: 978-1-58829-140-0
Online ISBN: 978-1-59259-399-6
eBook Packages: Springer Protocols